A Phase 3 interventional study of Tirzepatide and Placebo in Type 2 Diabetes, Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 75 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 17 in phase 3, and was the 19th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 938 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 28th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2021, is one of 85 in phase 3, and was the 170th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW)
Drug: Tirzepatide
15 mg Tirzepatide administered SC QW
Drug: Tirzepatide
Placebo administered SC QW
Other: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Percent Change From Baseline in Body Weight
Least Squares Mean (LSMean) calculated using Mixed Model Repeated Measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of Antihyperglycemic Medication (AHM) Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 72
Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline
Percentage of participants who achieve ≥5% body weight reduction from baseline
Time frame: Week 72
Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline
Percentage of participants who achieve ≥10% body weight reduction from baseline
Time frame: Week 72
Percentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline
Percentage of participants who achieve ≥15% body weight reduction from baseline
Time frame: Week 72
Percentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline
Percentage of participants who achieve ≥20% body weight reduction from baseline
Time frame: Week 72
Change From Baseline in Absolute Body Weight
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 72
Change From Baseline in Body Mass Index (BMI)
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 72
Change From Baseline in Hemoglobin A1c (HbA1c)
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 72
Percentage of Participants Who Achieve HbA1c <7%
Percentage of participants who achieve HbA1c \<7%
Time frame: Week 72
Percentage of Participants Who Achieve HbA1c ≤6.5%
Percentage of participants who achieve HbA1c ≤6.5%
Time frame: Week 72
Percentage of Participants Who Achieve HbA1c <5.7%
Percentage of participants who achieve HbA1c \<5.7%
Time frame: Week 72
Change From Baseline in Fasting Glucose
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 72
Change From Baseline in Waist Circumference
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 72
Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
Results are reported as model-based estimates and standard error (SE) from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide)
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)
LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 72
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)
LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 72
Percent Change From Baseline in Fasting Insulin
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score
The SF-36v2 acute, 1-week recall version is a 36-item, generic, patient-administered measure designed to assess the following 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" while the remaining domains assess functioning "in the past week." Each domain is scored individually and information from these 8 domains are further aggregated into 2 health-component summary scores: Physical-Component Summary and Mental-Component Summary. Items are answered on Likert scales of varying lengths (3-, 5-, or 6- point scales).The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
Time frame: Baseline, Week 72
Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score
The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life.
Time frame: Baseline, Week 72
Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide
Each participant was assigned via the Interactive Web Response System (IWRS) to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose. The steady state AUC was evaluated using Population PK modeling.
Time frame: Week 8, 16, 36: 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose
| Milestone | Placebo | 10 Milligrams (mg) Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Started | 315 | 312 | 311 |
| Received at least one dose of study drug | 315 | 312 | 311 |
| Completed | 281 | 296 | 282 |
| Not completed | 34 | 16 | 29 |
| Withdrew: Adverse event | 5 | 1 | 5 |
| Withdrew: Death | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 8 | 4 | 10 |
| Withdrew: Other - as reported by investigator | 3 | 2 | 2 |
| Withdrew: Pregnancy | 2 | 0 | 2 |
| Withdrew: Withdrawal by subject | 16 | 7 | 10 |
Least Squares Mean (LSMean) calculated using Mixed Model Repeated Measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of Antihyperglycemic Medication (AHM) Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
| percent change | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percent Change From Baseline in Body Weight | -3.3 ± 0.49 | -13.4 ± 0.48 | -15.7 ± 0.49 |
Percentage of participants who achieve ≥5% body weight reduction from baseline
| percentage of participants | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline | 30.55 | 81.55 | 86.41 |
Percentage of participants who achieve ≥10% body weight reduction from baseline
| percentage of participants | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline | 8.68 | 63.43 | 69.58 |
Percentage of participants who achieve ≥15% body weight reduction from baseline
| percentage of participants | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline | 2.57 | 41.42 | 51.78 |
Percentage of participants who achieve ≥20% body weight reduction from baseline
| percentage of participants | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline | 0.96 | 22.98 | 33.98 |
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
| kilograms (kg) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Change From Baseline in Absolute Body Weight | -3.2 ± 0.51 | -13.5 ± 0.51 | -15.6 ± 0.51 |
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
| kilograms per meter squared (kg/m^2) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | -1.2 ± 0.19 | -4.9 ± 0.18 | -5.7 ± 0.19 |
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
| percentage of HbA1c | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -0.16 ± 0.067 | -2.14 ± 0.060 | -2.22 ± 0.060 |
Percentage of participants who achieve HbA1c \<7%
| percentage of participants | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percentage of Participants Who Achieve HbA1c <7% | 29.31 | 90.03 | 90.67 |
Percentage of participants who achieve HbA1c ≤6.5%
| percentage of participants | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percentage of Participants Who Achieve HbA1c ≤6.5% | 15.52 | 84.05 | 86.67 |
Percentage of participants who achieve HbA1c \<5.7%
| percentage of participants | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percentage of Participants Who Achieve HbA1c <5.7% | 2.76 | 50.17 | 55.33 |
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| milligrams per deciliter (mg/dL) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Change From Baseline in Fasting Glucose | -2.42 ± 2.281 | -49.20 ± 1.940 | -51.67 ± 1.970 |
LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
| centimeters (cm) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Change From Baseline in Waist Circumference | -3.4 ± 0.51 | -11.2 ± 0.50 | -13.8 ± 0.51 |
Results are reported as model-based estimates and standard error (SE) from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | 2.13 ± 1.135 | -2.58 ± 0.755 |
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | 6.29 ± 1.874 | 2.72 ± 1.264 |
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | 1.10 ± 1.048 | 8.19 ± 0.782 |
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -6.0 ± 2.18 | -27.9 ± 1.16 |
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg) | -5.8 ± 2.32 | -28.6 ± 1.22 |
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled Doses of 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg) | 2.30 ± 1.573 | -6.64 ± 1.001 |
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide) | 0.03 ± 2.838 | -23.58 ± 1.502 |
LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
| millimeters of mercury (mmHg) | Placebo | Pooled 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide) | -1.0 ± 0.74 | -7.2 ± 0.52 |
LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
| millimeters of mercury (mmHg) | Placebo | Pooled Doses of 10 mg and 15 mg Tirzepatide |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide) | -0.2 ± 0.45 | -2.6 ± 0.31 |
Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
| percent change | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Percent Change From Baseline in Fasting Insulin | -14.5 ± 3.39 | -29.6 ± 2.28 | -40.3 ± 1.99 |
The SF-36v2 acute, 1-week recall version is a 36-item, generic, patient-administered measure designed to assess the following 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" while the remaining domains assess functioning "in the past week." Each domain is scored individually and information from these 8 domains are further aggregated into 2 health-component summary scores: Physical-Component Summary and Mental-Component Summary. Items are answered on Likert scales of varying lengths (3-, 5-, or 6- point scales).The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
| score on a scale | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score | 1.6 ± 0.40 | 3.4 ± 0.39 | 3.8 ± 0.40 |
The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life.
| score on a scale | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score | 7.4 ± 1.03 | 14.3 ± 1.00 | 15.2 ± 1.03 |
Each participant was assigned via the Interactive Web Response System (IWRS) to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose. The steady state AUC was evaluated using Population PK modeling.
| nanograms*hour per milliliter (ng*h/mL) | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|
| Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide | 153000 ± 19.5 | 234000 ± 19.2 |
Collected over Baseline through Week 76. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/315 (0%) | 23/315 (7.3%) | 158/315 (50.2%) |
| 10 mg Tirzepatide | 2/312 (0.6%) | 18/312 (5.8%) | 169/312 (54.2%) |
| 15 mg Tirzepatide | 0/311 (0%) | 27/311 (8.7%) | 159/311 (51.1%) |
| Event | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 1/315 | 3/312 | 0/311 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/156 | 0/154 | 1/152 |
| Pancreatitis acuteGastrointestinal disorders | 0/315 | 0/312 | 2/311 |
| Cholecystitis acuteHepatobiliary disorders | 2/315 | 1/312 | 2/311 |
| CholelithiasisHepatobiliary disorders | 1/315 | 0/312 | 2/311 |
| CellulitisInfections and infestations | 0/315 | 0/312 | 2/311 |
| Ischaemic strokeNervous system disorders | 0/315 | 0/312 | 2/311 |
| GastroenteritisInfections and infestations | 0/315 | 2/312 | 0/311 |
| Covid-19 pneumoniaInfections and infestations | 2/315 | 0/312 | 1/311 |
| AdenomyosisReproductive system and breast disorders | 0/159 | 1/158 | 0/159 |
| Event | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| NauseaGastrointestinal disorders | 20/315 | 63/312 | 68/311 |
| DiarrhoeaGastrointestinal disorders | 28/315 | 62/312 | 66/311 |
| Covid-19Infections and infestations | 53/315 | 52/312 | 33/311 |
| HyperglycaemiaMetabolism and nutrition disorders | 45/315 | 6/312 | 4/311 |
| VomitingGastrointestinal disorders | 10/315 | 34/312 | 40/311 |
| Decreased appetiteMetabolism and nutrition disorders | 7/315 | 30/312 | 31/311 |
| ConstipationGastrointestinal disorders | 13/315 | 25/312 | 28/311 |
| Abdominal painGastrointestinal disorders | 7/315 | 12/312 | 23/311 |
| DyspepsiaGastrointestinal disorders | 10/315 | 23/312 | 22/311 |
| Upper respiratory tract infectionInfections and infestations | 21/315 | 10/312 | 12/311 |
All randomized participants.
| Age, Continuous(years) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|
| Mean | 54.7 ± 10.5 | 54.3 ± 10.7 | 53.6 ± 10.6 | 54.2 ± 10.6 |
| Sex: Female, Male(Participants) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|
| Female | 159 | 158 | 159 | 476 |
| Male | 156 | 154 | 152 | 462 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|
| Hispanic or Latino | 188 | 184 | 189 | 561 |
| Not Hispanic or Latino | 122 | 124 | 112 | 358 |
| Unknown or Not Reported | 5 | 4 | 10 | 19 |
| Race (NIH/OMB)(Participants) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 39 | 44 | 42 | 125 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 3 |
| Black or African American | 22 | 33 | 22 | 77 |
| White | 248 | 228 | 234 | 710 |
| More than one race | 5 | 6 | 12 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|
| Argentina | 116 | 115 | 115 | 346 |
| Brazil | 30 | 29 | 30 | 89 |
| India | 9 | 8 | 9 | 26 |
| Japan | 21 | 24 | 22 | 67 |
| Russia | 17 | 13 | 13 | 43 |
| Taiwan | 8 | 9 | 8 | 25 |
| United States | 114 | 114 | 114 | 342 |
| Weight(kilograms (kg)) | Placebo | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|
| Mean | 101.65 ± 22.26 | 100.86 ± 20.93 | 99.60 ± 20.05 | 100.71 ± 21.10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Time Frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · www.vivli.org
Ran from Mar 2021 to primary completion in Mar 2023, 23 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide